Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of
breast cancer tumors. It is associated with a more aggressive disease, higher recurrence …

Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but
an effective targeted therapy has not been well-established so far. Considering the lack of …

Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

Abstract PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates
critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations …

The development of resistance to chemotherapy is a major obstacle for lasting effective
treatment of cancer. Here, we demonstrate that endogenous mesenchymal stem cells …

Background Increasing data indicate that HER2-positive (HER2+) breast cancer (BC)
subtypes exhibit differential responses to targeted anti-HER2 therapy. This study aims to …

In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial
with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …

Background Central nervous system (CNS) disease as the site of first relapse after exposure
to adjuvant trastuzumab has been reported. We carried out comprehensive meta-analysis to …

Breast cancer has a high incidence worldwide. The results of substantial studis reveal that
inflammation plays an important role in the initiation, development, and aggressiveness of …

Abstract Tumor protein p53 (TP53) is mutated in approximately 30% of breast cancers, but
this frequency fluctuates widely between subclasses. We investigated the p53 mutation …